Literature DB >> 12403988

Treatment of mood disorders.

Charles B Nemeroff1, Michael J Owens.   

Abstract

Depression is a leading cause of morbidity and mortality, and its treatment includes a high percentage of the medications prescribed by physicians. Available antidepressant drugs are safe and effective, but less than half of all patients attain complete remission after therapy with a single antidepressant. Others exhibit partial, refractory or intolerant responses to treatment, emphasizing the need to discover new antidepressants. The mechanisms of action of available medications are directing the field toward new research avenues. This review highlights those areas we believe will influence the field and soon lead to better treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12403988     DOI: 10.1038/nn943

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   24.884


  58 in total

Review 1.  Vagus nerve stimulation (VNS) for depression: what do we know now and what should be done next?

Authors:  Ziad Nahas; Carol Burns; Milton J Foust; Baron Short; Tal Herbsman; Mark S George
Journal:  Curr Psychiatry Rep       Date:  2006-12       Impact factor: 5.285

2.  Melatonin Augments the Effects of Fluoxetine on Depression-Like Behavior and Hippocampal BDNF-TrkB Signaling.

Authors:  Kun Li; Si Shen; Yu-Tian Ji; Xu-Yun Li; Li-San Zhang; Xiao-Dong Wang
Journal:  Neurosci Bull       Date:  2017-10-31       Impact factor: 5.203

Review 3.  Endocrine disturbances in depression.

Authors:  M A Tichomirowa; M E Keck; H J Schneider; M Paez-Pereda; U Renner; F Holsboer; G K Stalla
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

4.  Involvement of NO/cGMP pathway in the antidepressant-like effect of gabapentin in mouse forced swimming test.

Authors:  Sattar Ostadhadi; Nastaran Kordjazy; Arya Haj-Mirzaian; Sanaz Ameli; Golnoosh Akhlaghipour; AhmadReza Dehpour
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-01-12       Impact factor: 3.000

5.  Genome-wide approaches to antidepressant treatment: working towards understanding and predicting response.

Authors:  Karen Hodgson; Shaista Jeelani Mufti; Rudolf Uher; Peter McGuffin
Journal:  Genome Med       Date:  2012-06-27       Impact factor: 11.117

6.  Antidepressant-like effects of ferulic acid: involvement of serotonergic and norepinergic systems.

Authors:  Jianliang Chen; Dan Lin; Chong Zhang; Gaowen Li; Nianping Zhang; Lina Ruan; Qizhi Yan; Jianxin Li; Xuefeng Yu; Xupei Xie; Cong Pang; Liang Cao; Jianchun Pan; Ying Xu
Journal:  Metab Brain Dis       Date:  2014-12-09       Impact factor: 3.584

7.  Signaling pathways underlying the antidepressant-like effect of inosine in mice.

Authors:  Filipe Marques Gonçalves; Vivian Binder Neis; Débora Kurrle Rieger; Mark William Lopes; Isabella A Heinrich; Ana Paula Costa; Ana Lúcia S Rodrigues; Manuella P Kaster; Rodrigo Bainy Leal
Journal:  Purinergic Signal       Date:  2016-12-13       Impact factor: 3.765

8.  Suppressed neuroendocrine stress response in depressed women on job-stress-related long-term sick leave: a stable marker potentially suggestive of preexisting vulnerability.

Authors:  Kristina Wahlberg; Per Hamid Ghatan; Sieglinde Modell; Ake Nygren; Martin Ingvar; Marie Asberg; Markus Heilig
Journal:  Biol Psychiatry       Date:  2008-12-05       Impact factor: 13.382

9.  Emergence of anxiety-like behaviours in depressive-like Cpe(fat/fat) mice.

Authors:  Ramona M Rodriguiz; John J Wilkins; Thomas K Creson; Reeta Biswas; Iryna Berezniuk; Arun D Fricker; Lloyd D Fricker; William C Wetsel
Journal:  Int J Neuropsychopharmacol       Date:  2013-02-27       Impact factor: 5.176

Review 10.  Neuroimmunomodulation in depression: a review of inflammatory cytokines involved in this process.

Authors:  Helena M Abelaira; Gislaine Z Réus; Fabricia Petronilho; Tatiana Barichello; João Quevedo
Journal:  Neurochem Res       Date:  2014-07-05       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.